Latest revenue
$0
as of 2024-09-30
Latest net income
$-2.9M
as of 2024-09-30
Net margin
—
as of 2024-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.63B
- Enterprise value
- $1.63B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $151.18
- 52-wk low
- $20.20
- Beta
- —
- Shares out
- 14.3M
5-year trend
What this company does
Item 1. Business. On December 13, 2024, we completed the previously announced business combination with Legacy Palvella in accordance with the terms of the Merger Agreement, pursuant to which, among other matters, Merger Sub merged with and into Legacy Palvella, with Legacy Palvella surviving as our wholly owned subsidiary (such business combination, the Merger). In connection with the completion of the Merger, we changed our name from “Pieris Pharmaceuticals, Inc.” to “Palvella Therapeutics, Inc.,” and our business became primarily the business conducted by Legacy Palvella. We are now a clinical-stage biopharmaceutical company focused on developing and, if approved, commercializing novel…
AI summary unavailable — showing raw filing excerpt
Generated from PVLA's filing dated 2026-03-31
Key risks
Item 1A. Risk Factors. Investing in our securities involves risks. Before you make a decision to buy our securities, in addition to the risks and uncertainties discussed above under “Cautionary Note Regarding Forward-Looking Statements,” you should carefully consider the specific risks set forth herein. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Risks Related to Our Limited Operating…
AI summary unavailable — showing raw filing excerpt
Generated from PVLA's filing dated 2026-03-31
Profitability
Operating margin
-1490.4%
32.1%Net margin
-1610.6%
40.7%Return on equity
-149.1%
736.9%Return on assets
-70.0%
254.5%Leverage
Debt / equity
1.13×
151.7%Debt / assets
53.0%
71.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-15.8M | -92.6% | — |
Q4 2025 2025-12-31 | — | — | $-12.7M | -51.0% | — |
Q3 2025 2025-09-30 | — | — | $-11.3M | -293.0% | — |
Q2 2025 2025-06-30 | — | — | $-9.5M | -163.8% | — |
Q1 2025 2025-03-31 | — | — | $-8.2M | -222.8% | — |
Q4 2024 2024-12-31 | $636.0K | — | $-8.4M | — | -1324.1% |
Q3 2024 2024-09-30 | $0 | -100.0% | $-2.9M | +73.1% | — |
Q2 2024 2024-06-30 | $0 | +100.0% | $-3.6M | -190.3% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on PVLA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$850.0K
Insider selling
$2.6M
Net activity
−$1.8M
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns PVLA
Institutional value
$518.7M
Total shares held
4.2M
Distinct holders
95
-45 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 686.9K | $85.6M | +127.8K (+22.9%) | Added |
| 2 | JENNISON ASSOCIATES LLC | 640.6K | $79.9M | +253.1K (+65.3%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 477.3K | $59.5M | — | New |
| 4 | FEDERATED HERMES, INC. | 433.0K | $54.0M | +65.0K (+17.7%) | Added |
| 5 | PRIMECAP MANAGEMENT CO/CA/ | 195.0K | $24.3M | — | New |
| 6 | Artisan Partners Limited Partnership | 193.8K | $24.2M | -17.8K (-8.4%) | Trimmed |
| 7 | EMERALD ADVISERS, LLC | 161.5K | $20.1M | — | New |
| 8 | EMERALD MUTUAL FUND ADVISERS TRUST | 105.8K | $13.2M | — | New |
| 9 | UBS Group AG | 104.5K | $13.0M | +68.0K (+186.4%) | Added |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 90.9K | $11.3M | — | New |
| 11 | Clio Asset Management LLC | 90.8K | $11.3M | -885 (-1.0%) | Trimmed |
| 12 | abrdn plc | 81.1K | $10.1M | — | New |
| 13 | Avidity Partners Management LP | 70.0K | $9.0M | +50.7K (+262.7%) | Added |
| 14 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 69.9K | $8.7M | +22.2K (+46.6%) | Added |
| 15 | VANGUARD FIDUCIARY TRUST CO | 64.8K | $8.1M | — | New |
| 16 | SEVEN GRAND MANAGERS, LLC | 60.0K | $7.5M | — | New |
| 17 | Clearbridge Investments, LLC | 59.4K | $7.4M | -1.2K (-2.0%) | Trimmed |
| 18 | Invesco Ltd. | 48.5K | $6.0M | -5.7K (-10.6%) | Trimmed |
| 19 | Lisanti Capital Growth, LLC | 41.4K | $5.2M | -25 (-0.1%) | Trimmed |
| 20 | Ensign Peak Advisors, Inc | 39.2K | $4.9M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once PVLA's latest filing finishes processing.